title: Phentermine and topiramate extended release (Qsymia™): first global approval.
abstract: Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed to produce weight loss by decreasing appetite and increasing satiety. The product is also in clinical development for sleep apnoea syndrome and type 2 diabetes mellitus. This article summarizes the milestones in the development of phentermine/topiramate ER leading to this first approval for obesity.
authors.affiliation: Adis R&D Insight, Springer Healthcare, Auckland, New Zealand.
authors.forename: Fiona
authors.initials: F
authors.lastname: Cameron
authors.forename: Glenn
authors.initials: G
authors.lastname: Whiteside
authors.forename: Kate
authors.initials: K
authors.lastname: McKeage
mesh_terms: D019440:Anti-Obesity Agents / Q000008:administration & dosage*; D001067:Appetite Depressants / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D005632:Fructose / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D010645:Phentermine / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D000077236:Topiramate
chemical_list: D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D003692:Delayed-Action Preparations; D000077236:Topiramate; D005632:Fructose; D010645:Phentermine